BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
66.80
-0.75 (-1.11%)
Jun 12, 2026, 4:00 PM EDT - Market closed
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $194.52M in the quarter ending March 31, 2026, with 66.78% growth. This brings the company's revenue in the last twelve months to $579.96M, up 355.17% year-over-year. In the year 2025, BridgeBio Pharma had annual revenue of $502.08M with 126.26% growth.
Revenue (ttm)
$579.96M
Revenue Growth
+355.17%
P/S Ratio
22.56
Revenue / Employee
$691,249
Employees
839
Market Cap
13.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 502.08M | 280.17M | 126.26% |
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | 40.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Ascendis Pharma | 998.25M |
| Axsome Therapeutics | 708.24M |
BBIO News
- 8 days ago - BridgeBio Pharma Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 9 days ago - Canaccord starts BridgeBio on Attruby launch, pipeline - TheFly
- 9 days ago - BridgeBio Pharma Slides: Corporate presentation - Filings
- 9 days ago - BridgeBio initiated with a Buy at Canaccord - TheFly
- 15 days ago - BridgeBio price target raised to $98 from $94 at Morgan Stanley - TheFly
- 16 days ago - BridgeBio announces FDA acceptance, priority review of BBP-418 NDA - TheFly
- 16 days ago - BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 - GlobeNewsWire
- 17 days ago - BridgeBio downgraded to Market Perform from Outperform at Raymond James - TheFly